Dear Shareholder,
We are pleased to provide you with an update on several important developments across Minomic’s commercial and clinical programs, both in the US and now in the UK and Europe.
UK and European Commercial Partnership
We are pleased to advise that Minomic has entered into a commercial partnership with Addaptive Group Holdings (AGH), a UK-based entity, and its subsidiary IDC https://www.uhsidc.co.uk/ for the commercialisation of MiCheck® Prostate in the United Kingdom, Europe, and the Middle East.
IDC has experience in developing and deploying commercially advanced biotechnologies with NHS trusts, including obtaining UK regulatory approvals for new technologies. IDC will provide operational and service delivery support for Minomic in the UK and Europe. AGH provides commercial leadership and access to investors in these regions to support Minomic’s market entry and growth.
Under the terms of the arrangement, AGH’s commercial incentives are aligned with Minomic’s performance through a series of performance-based milestones tied to key regulatory approvals and revenue growth.
We regard this partnership as a significant step in expanding MiCheck® Prostate’s commercial footprint beyond Australia and the United States.
Prostate Cancer Research UK Engagement
Minomic has initiated discussions with Prostate Cancer Research UK (“PCR UK”) to support our UK market entry and broader investor strategy. The first workstream involves leveraging PCR UK’s existing Cost Benefit Analysis (CBA) model, which has already been developed and can be adapted to evaluate how MiCheck® Prostate will improve patient outcomes while reducing unnecessary MRI utilization and biopsies within the NHS prostate cancer pathway.
In parallel, we are preparing an Expression of Interest for PCR UK’s investment arm, with the goal of being included in their upcoming investment review process. While participation in PCR UK’s planned early screening study would be a longer-term opportunity, it represents a potential pathway for generating additional UK-specific clinical and health economic evidence.
We believe that engagement and potential endorsement from PCR UK will create significant strategic value for Minomic, enhancing credibility with UK, European, and U.S. investors while supporting future commercialization and partnership opportunities.
________________________________________
UK Clinical Program – NHS NICE Engagement
Together with Minomic’s clinical team and our UK partners, we have just completed a series of productive meetings in the United Kingdom, including meetings with leading UK urologists and prostate cancer pathway specialists associated with the Bristol NHS Trust and the UK’s National Institute for Health and Care Excellence (NICE).
Minomic’s engagement with the NHS NICE team is a major endorsement of Minomic’s technology as an early-stage tool to diagnose prostate cancer, an issue that has become a highly political topic in the UK, with one globally recognised celebrity calling for greater awareness and earlier diagnosis this week.
The NICE discussions confirmed a clear and compelling clinical position for MiCheck® Prostate within the NHS diagnostic pathway. The NICE clinical advisors identified several opportunities within the PIRADS 3 patient cohort – a group presenting significant diagnostic uncertainty following MRI – and younger males who do not respond as well to MRI scans as a priority opportunity.
In their view, MiCheck® Prostate has strong potential to help stratify these patients and guide biopsy decisions by radiologists across the country, reduce unnecessary biopsies, and support more efficient use of limited NHS resources for cancer patients who need treatment now.
Bristol NHS has advised that they have an existing infrastructure for a biomarker-based clinical study, and the NHS specialists we met with have indicated both the capability and appetite to recruit patients for a prospective study.
A follow-up meeting is being scheduled to progress study design and budgeting. Given the national focus on prostate cancer at present in the UK, a defined study protocol will help open UK and European investor backing and assist with Minomic’s aim to list in 2027.
We believe the engagement with the NHS and NICE key opinion leaders should establish MiCheck® Prostate as the leading biomarker test within the UK urology community over time.
________________________________________
European Clinical Program
In parallel, Minomic has begun discussions with one of Europe’s largest providers of advanced diagnostic imaging and outpatient healthcare services, with operations across multiple European markets. The prospective partner operates one of Europe’s largest MRI networks, providing access to a substantial patient population and clinical infrastructure across multiple countries.
These discussions have been very encouraging. The counterparty has expressed strong interest in partnering with Minomic on a European pilot study. Their preferred positioning for MiCheck® Prostate – as a pre-biopsy triage tool – is consistent with how the test is currently deployed in the United States and complements the NHS-focused pathway approach being developed in the UK.
There is also the opportunity, as part of the trials, to integrate the MiCheck® Prostate data with the data from our partners’ MRI machines using AI to provide radiologists with a powerful tool for patient diagnostics.
The prospective partner has indicated the infrastructure and patient access to recruit up to approximately 500 patients, which would generate meaningful clinical utility data and support analytical validation across the European market.
Importantly, the proposed study is expected to be fully funded by our European partner rather than by Minomic. If confirmed, this would allow Minomic to generate significant European clinical evidence supported by our partners’ own financial resources.
We expect to be in a position to provide a further update on this opportunity in the coming weeks.
________________________________________
United States Update
Minomic continues to advance the commercial rollout of MiCheck® Prostate in the United States through both reference laboratory and physician office laboratory (POL) channels. During the quarter, the Company expanded engagement with leading community and academic urology groups and continues to receive positive feedback regarding MiCheck® Prostate’s ability to improve patient risk stratification and support biopsy decision-making.
In parallel, Minomic has continued preparations for its U.S. FDA clinical program, including engagement with prospective study sites, principal investigators, and regulatory advisors. These activities are intended to support a future multi-centre clinical study while generating additional evidence to strengthen reimbursement and commercialization efforts.
The Company believes the combination of growing physician engagement, expanding commercial opportunities, and continued regulatory progress positions MiCheck® Prostate well for future growth in the U.S. market.
________________________________________
Summary
The Board is encouraged by the consistency of feedback received from clinical, commercial, and investor stakeholders across the United States, the United Kingdom, and Europe. MiCheck® Prostate continues to demonstrate potential to improve prostate cancer risk stratification while supporting more efficient utilization of diagnostic resources.
We believe the Company has entered an important phase in its evolution, with commercial, clinical and regulatory initiatives now progressing simultaneously across Australia, the United States, the United Kingdom and Europe. We will keep shareholders informed as these programs develop.
Warmest Regards,
Sushmita Utpala,
CEO Minomic International Ltd
July 2026
